RajaMudadMDFACP

Oncology • Doral, FL

Thoracic Cancer

Associate Professor Sylvester Comprehensive Cancer Center

Join to view full profile

Dr. Mudad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mudad's full profile

Already have an account?

Office
8333 NW 53rd street
first floor
Doral, FL 33166

Summary

Facebook: Dr. Raja Mudad
Twitter: @DrMudad

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1992 - 1995
Duke University HospitalResidency, Internal Medicine, 1989 - 1992
American University of Beirut Faculty of MedicineClass of 1989

Certifications & Licensure

FL State Medical License 2006 - 2026
LA State Medical License 1995 - 2009
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Most Compassionate Doctor American Registry

Clinical Trials

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Feb 11
Active, not recruiting
Phase 3
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Start of enrollment: 2014 Sep 26
Recruiting
Not Applicable
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Mar 23
Recruiting
Phase 3
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Feb 01
Completed
Phase 1
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC Start of enrollment: 2015 Nov 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

25 citations
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
Wungki Park, Laura Mezquita, Naoyuki Okabe, Young Kwang Chae, Deukwoo Kwon
British Journal of Cancer. 2020-02-04
16 citations
EGFR Mutation Testing: Changing Patterns of Molecular Testing in Brazil
Sofia Palacio, Lucíola de Barros Pontes, Edna Prado, Junaid Arshad, Robert A. Ali
The Oncologist. 2019-04-01
18 citations
Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
Robert A. Ali, Junaid Arshad, Sofia Palacio, Raja Mudad
Drug Design, Development and Therapy. 2019-02-08

Lectures

“Adjuvant Targeted Therapy in NSCLC"
Panama City, Panama - 8/26/2016
The patient as a Unique Individual
San Francisco, California, "The Living Room" Bonnie Addario Lung Cancer Foundation - 5/17/2016

Press Mentions

Selective RET Inhibitors for RET Fusion-Positive Non-Small Cell Lung CancerMarch 27th, 2023
Sylvester Celebrates Doral Satellite OpeningSeptember 13th, 2022
Mesothelioma Clinical Trial Opens with Optimism in South FloridaApril 4th, 2018
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Arabic, French, Spanish